Targeting aging cells to improve treatment for pancreatic cancer
Official title: Targeting cellular senescense in pancreatic cancer
Funded at Translational Genomics Research Inst · NIH-11113721 · Data updated 2026-11-12
This study is looking at how getting rid of certain old cells in the body might help make pancreatic cancer treatments work better, and it’s inviting patients to join trials to see if this new method is safe and effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $269,280 |
| NIH project number | 1R21CA299593-01 |
| Project ID | NIH-11113721 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who are undergoing standard cancer treatments.
✕Less likely to help
Patients with early-stage pancreatic cancer or those not receiving standard therapies may not benefit from this research.
What this research studies
This research investigates how targeting cellular senescence, a process where cells stop dividing, can affect pancreatic cancer treatment. It focuses on the role of senescent cells in creating a tumor-friendly environment that hinders effective therapy. By using a specific antibody to eliminate these senescent cells, the study aims to enhance the effectiveness of standard chemotherapy and immune therapies. Patients may be involved in trials to assess the safety and efficacy of this new approach.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting cellular senescence in other cancer types, suggesting potential for success in this novel approach for pancreatic cancer.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Han, Haiyong — Translational Genomics Research Inst
- Study coordinator: Han, Haiyong
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.